Abstract
In this paper we provide an overview of some of the ways in which phase I packages can be tailored to the needs of the specific compound and conducted more efficiently using combination, flexible protocols. We outline the considerations that need to be made at the planning stage and how to make best use of emerging PK and safety data to enable informed decisions regarding study progression. A case study further illustrates how pharmacokinetics, safety, and tolerability of doses can be evaluated.
Get full access to this article
View all access options for this article.
References
1.Association of the British Pharmaceutical Industry . Guidelines for phase I clinical trials . 2007 . www.abpi.org.uk/publications
2.Committee for Medicinal Products for Human Use (CHP) . Guideline on strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products . 2007 . http://www.ema.europa.eu/docs
3.Association of the British Pharmaceutical Industry . First in human studies: points to consider in study placement, design and conduct . 2011 . www.abpi.org.uk/publications